Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069745 · ClinicalTrials.gov registry record · Phase 3
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
A Phase 3 study, sponsored by Agennix.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00069745: Completed Phase 3 study, sponsored by Agennix.
NCT00069745 is a Phase 3 study that has completed, run by Agennix. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00069745, a Phase 3 study, has completed, sponsored by Agennix.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
PURPOSE: The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC). TARGET PATIENT POPULATION: The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria. WHAT IS SATRAPLATIN: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial. RATIONALE: There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy
Interventions
- DRUG Prednisone
- DRUG Satraplatin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
What the finished NCT00069745 record still lists
NCT00069745 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT00069745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00069745 about?
NCT00069745 is a clinical study titled "Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen". PURPOSE: The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC). TARGET PATIENT POPULATION: The SPARC trial is in...
What is the current status of trial NCT00069745?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00069745?
The interventions under investigation include: Prednisone (DRUG), Satraplatin (DRUG).
Who is sponsoring clinical trial NCT00069745?
This trial is sponsored by Agennix, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia